Unequal CAB count means US delay on MRA (mutual recognition agreement):
This article was originally published in Clinica
Following a long silence on the mutual recognition agreement(MRA) between the EU and the US, which most observers had expected would be officially adopted by now, it now seems that more observed audits will need to take place in the US before full implementation can take place. Indications are that the US now wants to ensure that it has as many conformity assessment bodies as the EU (currently it has three, compared to six in the EU). The speed at which the CABs can be recognised as ready for listing will depend on industry's willingness to invite potential conformity assessment bodies based in the US to take part in observed audits. In the past, companies were slow to put themselves forward and it is unclear what the situation is now.
You may also be interested in...
China's centralized procurement scheme, if further expanded after causing the prices of 32 drugs to be cut by more than half in the latest round, will leave companies no room to breathe easy amid the already devastating coronavirus outbreak, analysts say.
Sangamo licensed Biogen zinc finger protein transcription factor candidates in an alliance worth over $2bn. Exercising an option it gained in 2017, Takeda bought celiac disease-focused PvP Biologics for up to $330m in earn-outs. A strong showing of IPOs prompted biopharma financing to increase from last month.
With many non-CE marked products being allowed onto various EU member state markets, who is going to monitor compliance? TÜV-SÜD’s Bassil Akra calls for cooperation to avoid unsafe products being used on patients.